WHO recommends a twice-a-year injection for HIV prevention
This landmark guidance, released at the 13th International AIDS Society Conference in Kigali on July 14 – as concern looms over funding for the global HIV fight – endorses the drug's use every six months, marking a pivotal shift from daily pills to long‑acting, needle‑delivered protection.
What is Lenacapavir?
Lenacapavir (brand names Sunlenca for treatment, Yeztugo for prevention) is a long‑acting capsid inhibitor that has redefined HIV prevention.
Administered via injection just twice a year, it works by targeting the structural protein (capsid) of the HIV, blocking its ability to replicate in the body.
Lenacapavir was approved in 2022 to treat certain HIV infections, and in trials for prevention, it was found to dramatically reduce the risk of infection and provide almost total protection against HIV.
WHO's official recommendation
Dr. Meg Doherty, director of WHO's Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, said in a news briefing, 'These new recommendations are designed for real-world use.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Is it legal? How to get Internet without paying a subscription?
Techno Mag
Learn More
Undo
WHO is working closely with countries and partners to support the implementation.' Doherty added, 'The first recommendation is that a long-acting injectable, lenacapavir, should be offered as an additional prevention choice for people at risk for HIV and as part of combination prevention.
With that, we call it a strong recommendation with moderate to high certainty of the evidence.'
The second recommendation in the guidelines is that rapid diagnostic tests, like at-home tests, can be used to screen someone for HIV when they are starting, continuing, or stopping long-acting medication to prevent infection, called pre-exposure prophylaxis, or PrEP.
Health leaders, including WHO's Director‑General Dr. Tedros Adhanom Ghebreyesus, touted lenacapavir as 'the next best thing' to an HIV vaccine.
This latest endorsement complements existing WHO‑approved prevention methods – daily oral PrEP, bi‑monthly cabotegravir injections, and the dapivirine vaginal ring.
WHO also streamlined HIV testing protocols to support injectable PrEP uptake in community settings, pharmacies, and telehealth contexts.
Why a twice‑yearly injection might prove to be a good shot
Adherence and convenience:
Daily pill demands consistency, which many at‑risk individuals struggle to maintain. Lenacapavir simplifies prevention to two clinic visits per year, helping sidestep barriers like stigma, pill fatigue, or limited healthcare access.
Effectiveness:
Purpose trial data
speaks volumes: in one study, zero infections occurred among participants receiving lenacapavir, compared to significant infection rates in the pill‑based PrEP group.
Equity and access:
High‑risk populations – sex workers, LGBTQ+ individuals, people who inject drugs, incarcerated people, adolescents – stand to gain most from an easy‑to‑administer, long‑lasting prevention tool.
What is HIV/AIDS?
HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection, making a person more vulnerable to other infections and diseases. It is spread by contact with certain bodily fluids of a person with HIV, most commonly during unprotected sex (sex without a condom or HIV medicine to prevent or treat HIV), or through sharing injection drug equipment.
If left untreated, HIV can lead to the disease AIDS (acquired immunodeficiency syndrome).
Within a few weeks of HIV infection, flu-like symptoms such as fever, sore throat, and fatigue can occur. Then the disease is usually asymptomatic until it progresses to AIDS. AIDS symptoms include weight loss, fever or night sweats, fatigue, and recurrent infections.
There is no existing cure for AIDS, but strict adherence to antiretroviral regimens (ARVs) can dramatically slow the disease's progress as well as prevent secondary infections and complications.
Vaccines for HIV are under trial, but no effective vaccine has been developed to date.
In early 2025, the global fight against HIV/AIDS faced a significant setback with the United States of America's decision to halt foreign aid funding for HIV prevention and treatment programs. This move, part of a broader 90-day pause in US foreign development assistance, sent shockwaves through the international health community only a week ago, raising alarms about a potential resurgence of the epidemic.
WHO's endorsement of twice‑yearly lenacapavir marks a transformative moment, especially amidst the looming concerns regarding the funding cuts.
Gilead Sciences, maker of lenacapavir, recently announced that it has reached an agreement with the nonprofit Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir for HIV prevention at no profit to the company. Under this agreement, Gilead's pricing reflects only the cost of producing and delivering lenacapavir.
Gilead Chairman and CEO Daniel O'Day said in a news release, 'We are providing the medicine at no profit to Gilead, and in enough supply to reach up to two million people in low- and lower-middle-income countries ahead of generic lenacapavir becoming available.'
Peter Sands, executive director of the Global Fund, said in the news release, lenacapavir can 'fundamentally change the trajectory of the HIV epidemic,' but only if it reaches the people who need it most.
As per him, 'Our ambition is to reach 2 million people with long-acting PrEP. But we can only do that if the world steps up with the resources required. This is a pivotal moment — not just for the fight against HIV, but for the fundamental principle that lifesaving innovations must reach those who need them most — whoever they are, and wherever they live.'
If scaled equitably and thoughtfully, this intervention could reshape the landscape of HIV prevention, moving us closer to a world without AIDS.
Actor Nargis Fakhri Reveals 9‑Day Water Fast Twice a Year to Get 'Snatched'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
14 minutes ago
- Time of India
Gujarat high court grants bail to director, marketing execs of Khyati Hospital
Ahmedabad: The Gujarat high court on Tuesday granted bail to three accused persons – one director and two marketing executives of Khyati Hospital – in connection with the deaths of two PMJAY beneficiaries after they underwent angioplasty procedures at the hospital last year. The hospital has been accused of conducting the procedures wrongfully to avail benefits under the Pradhan Mantri Jan Arogya Yojana (PM-JAY) scheme last year. Justice M R Mengdey granted conditional bail to hospital director Chirag Rajput, marketing executive Pankil Patel, and marketing manager Pratik Bhatt, on each of them furnishing a personal bail bond of Rs 10,000 and surety of an equal amount. They approached the court for bail through advocate Ajj Murjani. You Can Also Check: Ahmedabad AQI | Weather in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad According to the prosecution, Rajput has a 6.8% share in the hospital. He was involved in the overall administration of the hospital and overaw the activities of the marketing team. It was alleged that he pressured the marketing team to bring more patients to the hospital, and with this intention, more medical camps were organised by Khyati Hospital. For Patel and Bhatt, it was alleged that they also persuaded the patients to undergo the procedures in question. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like American Investor Warren Buffett Recommends: 5 Books For Turning Your Life Around Blinkist: Warren Buffett's Reading List Undo Considering the gravity of the case, the role alleged on the part of these accused, and the possibility of their availability during the trial, the HC granted them bail on routine conditions, including marking presence before the Vastrapur police station once a month for six months. The city crime branch probed the case and arrested nine persons, including the hospital's chairman, Kartik Patel.
Time of India
an hour ago
- Time of India
HHS secretary Robert F Kennedy Jr fires two top aides; senior Trump official ousted, interim chief appointed
US health and human services secretary Robert F Kennedy Jr (Image credits: AP) US health and human services secretary Robert F Kennedy Jr has dismissed two top aides of the department, marking a sudden leadership shift just months into his tenure. Chief of staff Heather Flick Melanson and deputy chief of staff for Policy Hannah Anderson were removed from their roles this week, sources familiar with the matter told CNN. The possible reason behind the move remains unclear. An HHS spokesperson confirmed the changes and announced that Matt Buckham, the department's White House liaison, will take over as acting chief of staff. 'He brings valuable experience in personnel strategy and organizational management to this new role,' the spokesperson said as quoted by CNN. 'Secretary Kennedy thanks the outgoing leadership for their service and looks forward to working closely with Mr. Buckham as the Department continues advancing its mission to Make America Healthy Again,' he added. Kennedy has not yet chosen permanent replacements. The leadership overhaul comes as HHS faces mounting scrutiny over its efforts to revise vaccine policies and push forward key health and food initiatives. Flick was one of Kennedy's most seasoned Washington insiders, having held multiple senior roles at HHS during the Trump administration, including acting general counsel, acting secretary for administration, and senior adviser to then-Secretary Alex Azar. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is it legal? How to get Internet without paying a subscription? Techno Mag Learn More Undo Anderson came to HHS with a background as a Republican staffer on Capitol Hill, where she served as a health policy adviser on the Senate's primary health committee. Most recently, she led health care policy at the Trump-aligned America First Policy Institute.
New Indian Express
an hour ago
- New Indian Express
Amid US funding cuts, global health aid sinks to 15-year low in 'era of austerity'
PARIS: Sweeping foreign aid cuts led by the United States will cause international health funding to plummet to the lowest level in 15 years, a study said Wednesday, warning the world has entered a new "era of global health austerity." Money that provides healthcare to some of the poorest and most in-need people across the world has been dramatically slashed this year, led by the administration of US President Donald Trump. The new study published in the prestigious Lancet journal also pointed to recent steep aid cuts announced by the UK, France and Germany. After reaching an all-time high of $80 billion in 2021 during the Covid-19 pandemic, the total amount of global health aid will sink to $39 billion this year, the US-led team of researchers estimated. That would be the lowest level since 2009. Such a dramatic change will result in the world entering a new "era of global health austerity", the authors of the study warned. Sub-Saharan African countries such as Somalia, the war-torn Democratic of Congo and Malawi will be hit worst because most of their health funding currently comes from international aid, according to the study. The funding cuts will have a major impact on the treatment and prevention of a range of diseases, including HIV/AIDS, malaria and tuberculosis, it added The US slashed its global health funding by at least 67 percent in 2025 compared to last year, according to the research. The UK cut its funding by nearly 40 percent, following by France with 33 percent and Germany with 12 percent. The researchers at the US-based Institute for Health Metrics and Evaluation called for the world to urgently ramp up health aid. They also warned that nations would likely need find other sources of funding. The study was released as AIDS experts meet in Rwanda's capital Kigali for an international conference on HIV science. The US foreign aid cuts alone are estimated to result in the preventable deaths of more than 14 million people by 2030, according to a different Lancet study published earlier this month. For comparison, around 10 million soldiers were killed during World War I.
